• Citius Oncology, majority-owned subsidiary of Citius Pharma, shipped first international order of LYMPHIR to Europe via a regional distribution partner.
• European access will run through Named Patient Programs, expanding availability beyond initial US launch in December 2025.
• LYMPHIR lacks European marketing authorization; use will be limited to local Named Patient Program pathways.
• US label covers adult Stage I-III relapsed or refractory CTCL following at least one prior systemic therapy, with FDA clearance granted in August 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-049338), on April 29, 2026, and is solely responsible for the information contained therein.